Terbinafin-Mepha
Terbinafin-Mepha is a medicine authorised by Swissmedic under authorisation number 57865. The authorisation holder is Mepha Pharma AG. The medicinal product code is Synthetic medicines and the dispensing category is D: Supplied in pharmacies and drugstores after specialist advice, without a prescription. First authorisation was granted on 28 August 2007 and the authorisation is valid without a time limit. ATC code D01AE15 places the medicine in the group Antifungals for dermatological use.
| Authorisation number | 57865 |
|---|---|
| Name | Terbinafin-Mepha |
| Full name | Terbinafin-Mepha, Crème |
| Authorisation holder | Mepha Pharma AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | D · No prescription, with advice |
| ATC code | D01AE15 |
| First authorisation | 28 August 2007 |
| Authorisation validity | unlimited |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Terbinafin-Mepha, Crème | D | 28 August 2007 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 15 | g | D01AE15 | 10.09.4. | D |
Scroll the table sideways
Medicines in the same ATC group
Other medicines from this authorisation holder
Frequently asked questions
Is Terbinafin-Mepha authorised in Switzerland?
Yes. Terbinafin-Mepha is authorised by Swissmedic under authorisation number 57865, data as of 01 September 2026. The authorisation is valid without a time limit.
Which dispensing category does Terbinafin-Mepha have?
Terbinafin-Mepha is in dispensing category D. Supplied in pharmacies and drugstores after specialist advice, without a prescription.
Who is the authorisation holder of Terbinafin-Mepha?
The authorisation holder is Mepha Pharma AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.